Skip to content Skip to footer

Vueway Expands Pediatric Use: Alberto Spinazzi Shares Bracco Group’s Vision 

Shots:  The EU approval of Vueway for neonates, infants, and toddlers is a milestone for pediatric imaging as it allows high-quality MRI imaging at half the GBCA dose, supporting reduced gadolinium exposure in vulnerable young patients  Vueway’s gadopiclenol demonstrates safety and diagnostic performance by offering high stability, low dissociation risk, and 2.5–4× greater relaxivity than other macrocyclic GBCAs, enabling effective imaging…

Read more

Telix Pharmaceuticals

Telix Reports First US Patient Dosing in the P-III Trial of Illuccix and Gozellix, for the Diagnosis of Prostate Cancer

Shots: The company has reported dosing of the first patient in the US  P-III (BiPASS) trial evaluating its PSMA-PET imaging agents, Illuccix and Gozellix, for use in the initial diagnosis of prostate cancer BiPASSa P-III study enrolling 250 pts in the US and Australia to support marketing authorization of 68Ga-PSMA-PET in the pre-biopsy setting Building…

Read more